Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.43 |
| ▸ | PGD | P52209 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.30 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.30 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6301409 | 1.00 | SLC22A6 (0.43) | SLC22A6PGDMAPTGABRR1LMNA | |
| SCHEMBL4420207 | 0.82 | MAPK1 (0.32) | — | |
| SCHEMBL633699 | 0.81 | PGD (0.39) | PGD | |
| SCHEMBL16689224 | 0.80 | PGD (0.34) | PGD | |
| SCHEMBL15142159 | 0.80 | FFAR4 (0.41) | GPR84 | |
| SCHEMBL22289099 | 0.79 | PGD (0.33) | PGDLMNASMN1; SMN2 | |
| SCHEMBL3710989 | 0.79 | PGD (0.33) | PGDLMNASMN1; SMN2 | |
| SCHEMBL3710988 | 0.79 | PGD (0.33) | PGDLMNASMN1; SMN2 | |
| SCHEMBL8669335 | 0.78 | PGD (0.34) | PGD | |
| SCHEMBL17709437 | 0.77 | CYP2D6 (0.38) | ADRB2ADRB1ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6897324-B2 | Process for the preparation of 11-oxaprostaglandins and intermediates therein | CHIROTECH TECHNOLOGY LIMITED (GB) | 2005-05-24 | — | — | US | disclosed |
| US-20030166948-A1 | Process for the preparation of 11-oxaprostaglandins and intermediates therein | CHIROTECH TECHNOLOGY LIMITED (GB) | 2003-09-04 | — | — | US | disclosed |
| EP-1282627-A1 | PROCESS FOR THE PREPARATION OF 11-OXAPROSTAGLANDINS AND INTERMEDIATES THEREIN | Chirotech Technology Limited (GB) | 2003-02-12 | — | — | EP | disclosed |
| WO-2001087897-A1 | PROCESS FOR THE PREPARATION OF 11-OXAPROSTAGLANDINS AND INTERMEDIATES THEREIN | CHIROTECH TECHNOLOGY LIMITED (GB) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166948-A1 | Process for the preparation of 11-oxaprostaglandins and intermediates therein | CYP4A11, PTGER1, PTGIS | SLC22A6 3885/4885PGD 301/4885MAPT 4883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.